Status: Recruiting
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.
Participants needed: 25
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSUpdated: Feb 12, 2025Locations: 3
Eligibility criteria
written informed consent to study procedures; [+26]
patients experiencing PD as best response to EC; [+21]